TP-003 is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. It is a positive allosteric modulator at the benzodiazepine binding site of GABAA receptors.[1] It has modest anticonvulsant activity although less than that of diazepam.[2]
^Neumann E, Ralvenius WT, Acuña MA, Rudolph U, Zeilhofer HU (2018). "TP003 is a non-selective benzodiazepine site agonist that induces anxiolysis via α2GABAA receptors". Neuropharmacology. 143: 71–78. doi:10.1016/j.neuropharm.2018.09.026. PMID30240781. S2CID52313196.
^Fradley RL, Guscott MR, Bull S, Hallett DJ, Goodacre SC, Wafford KA, Garrett EM, Newman RJ, O'Meara GF, Whiting PJ, Rosahl TW, Dawson GR, Reynolds DS, Atack JR (Jun 2007). "Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands". Journal of Psychopharmacology. 21 (4): 384–91. doi:10.1177/0269881106067255. PMID17092983. S2CID34355306.
(what is this?) (verify)
